JP2023539715A5 - - Google Patents
Info
- Publication number
- JP2023539715A5 JP2023539715A5 JP2022580310A JP2022580310A JP2023539715A5 JP 2023539715 A5 JP2023539715 A5 JP 2023539715A5 JP 2022580310 A JP2022580310 A JP 2022580310A JP 2022580310 A JP2022580310 A JP 2022580310A JP 2023539715 A5 JP2023539715 A5 JP 2023539715A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical product
- product according
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043474P | 2020-06-24 | 2020-06-24 | |
| US63/043,474 | 2020-06-24 | ||
| PCT/IB2021/055549 WO2021260580A1 (en) | 2020-06-24 | 2021-06-23 | Combination of antibody-drug conjugate and atm inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539715A JP2023539715A (ja) | 2023-09-19 |
| JP2023539715A5 true JP2023539715A5 (https=) | 2024-06-28 |
Family
ID=76730927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580310A Pending JP2023539715A (ja) | 2020-06-24 | 2021-06-23 | 抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230256110A1 (https=) |
| EP (1) | EP4171651A1 (https=) |
| JP (1) | JP2023539715A (https=) |
| CN (1) | CN116194109A (https=) |
| TW (1) | TW202216209A (https=) |
| WO (1) | WO2021260580A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2024214685A1 (https=) * | 2023-04-10 | 2024-10-17 | ||
| AU2024263367A1 (en) * | 2023-04-27 | 2025-11-13 | CSPC Megalith Biopharmaceutical Co., Ltd. | Antibody-drug conjugate |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| NZ507557A (en) * | 1998-05-06 | 2003-10-31 | Genentech Inc | Protein purification by ion exchange chromatography |
| CN100340575C (zh) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| BR0307944A (pt) | 2002-02-25 | 2005-02-01 | Kudos Pharm Ltd | Piranonas úteis como inibidores de atm |
| AU2004265149A1 (en) | 2003-08-13 | 2005-02-24 | Kudos Pharmaceuticals Limited | Aminopyrones and their use as ATM inhibitors |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| WO2007133855A2 (en) | 2006-03-27 | 2007-11-22 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| IN2014DN06806A (https=) | 2012-02-10 | 2015-05-22 | Univ Maryland | |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| AU2014371934B2 (en) | 2013-12-25 | 2020-01-23 | Daiichi Sankyo Company, Limited | Anti-TROP2 antibody-drug conjugate |
| IL310627B2 (en) * | 2014-01-31 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof |
| KR102445502B1 (ko) | 2014-04-10 | 2022-09-21 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| NO2714752T3 (https=) | 2014-05-08 | 2018-04-21 | ||
| RS62082B1 (sr) | 2015-04-02 | 2021-08-31 | Merck Patent Gmbh | Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze |
| CN116059395A (zh) | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| GB201516504D0 (en) * | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| GB201519406D0 (en) | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| GB201519568D0 (en) | 2015-11-05 | 2015-12-23 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| GB201604182D0 (en) | 2016-03-11 | 2016-04-27 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| WO2017162611A1 (en) | 2016-03-21 | 2017-09-28 | Astrazeneca Ab | Quinoline-3-carboxamide compounds and their use in treating cancer |
| CN108884084A (zh) | 2016-03-21 | 2018-11-23 | 阿斯利康(瑞典)有限公司 | 噌啉-4-胺化合物及其在治疗癌症中的用途 |
| MA44603A (fr) | 2016-04-07 | 2019-02-13 | Astrazeneca Ab | Oxyde de n,n-diméthyl-3-[[5-(3-méthyl-2-oxo-1-tétrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine utilisé comme modulateur de la protéine kinase atm (ataxia telangiectasia mutated) pour traiter le cancer |
| GB201608227D0 (en) | 2016-05-11 | 2016-06-22 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| JOP20190209A1 (ar) | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
| TW202532104A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| IL324591A (en) | 2017-08-31 | 2026-01-01 | Daiichi Sankyo Co Ltd | Improved antibody-drug conjugate production methods |
| WO2019057757A1 (en) | 2017-09-20 | 2019-03-28 | Astrazeneca Ab | 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER |
-
2021
- 2021-06-23 US US18/012,900 patent/US20230256110A1/en active Pending
- 2021-06-23 CN CN202180050399.2A patent/CN116194109A/zh active Pending
- 2021-06-23 JP JP2022580310A patent/JP2023539715A/ja active Pending
- 2021-06-23 WO PCT/IB2021/055549 patent/WO2021260580A1/en not_active Ceased
- 2021-06-23 TW TW110122960A patent/TW202216209A/zh unknown
- 2021-06-23 EP EP21736709.3A patent/EP4171651A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539715A5 (https=) | ||
| JP2023542066A5 (https=) | ||
| JP2023545096A5 (https=) | ||
| JPWO2020122034A5 (https=) | ||
| JP2025041725A5 (https=) | ||
| ES2966473T3 (es) | Derivados de camptotecina | |
| JPWO2020130125A5 (https=) | ||
| JP2023525120A5 (https=) | ||
| JP2025160317A5 (https=) | ||
| JP2023070678A5 (https=) | ||
| JPWO2020059772A5 (https=) | ||
| JP2020019787A5 (https=) | ||
| JP2010535713A5 (https=) | ||
| JP2020509027A5 (https=) | ||
| RU2017139490A (ru) | Конъюгаты лекарственных средств, содержащие антитела против клаудина 18.2 | |
| JP2017095457A5 (https=) | ||
| JP2020526584A5 (https=) | ||
| JP2008500815A5 (https=) | ||
| TW202537975A (zh) | 抗體－藥物結合物之製造方法 | |
| JP2009505676A5 (https=) | ||
| JP2020500834A5 (https=) | ||
| JP2025507817A5 (https=) | ||
| JP2023510349A5 (https=) | ||
| TW201536319A (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| JP2023542065A5 (https=) |